|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alchemia Pty. Ltd., of Brisbane, Australia, and CelTor Biosystems, of Santa Clara, Calif., entered a collaboration to identify new compounds active against a variety of G protein-coupled receptor targets. The collaboration will combine AlchemiaEs Versatile Assembly on Sugar Templates (VAST) chemistry platform with CelTorEs CelBase Disease model technology to develop new drug candidates.
Abgenix Inc., of Fremont, Calif., and Diabetogen Biosciences Inc., of London, Ontario, executed a research and collaboration, option and license agreement to discover and develop a fully human monoclonal antibody therapy against an undisclosed antigen for the treatment of ...